The NPPA enforces a 30% trade margin cap on 137 non-scheduled anti-cancer drugs, reducing prices by up to 96% and saving consumers Rs 3,502 crore annually from November 9.

Strict enforcement of price caps to ensure patient access

Phased implementation allowing inventory adjustment periods

Subsidies to offset distributor margins without lowering prices

Economy & Markets India

2h ago

India Caps Anti-Cancer Drug Trade Margins to Slash Prices

Key Points

Eighty-five manufacturers reported revised prices for 1,364 formulations, saving consumers Rs 3,502 crore annually.
Six hundred seventy-nine brands saw cuts over 50%, with some prices dropping by nearly 96 percent.
State Drug Controllers will monitor compliance while patients face access hurdles in smaller towns.

Editorial Deep Dive & Context

Effective November 9, 2026, the National Pharmaceutical Pricing Authority (NPPA) implemented revised maximum retail prices for 137 non-scheduled anti-cancer formulations following recommendations from the Directorate General of Health Services. The regulatory intervention caps trade margins at 30%, targeting excessive mark-ups that previously reached 700%.

As of early November, 85 pharmaceutical manufacturers submitted revised pricing structures covering 1,364 formulations across 121 distinct drugs. The Ministry of Chemicals and Fertilizers estimates this policy will deliver annual consumer savings of approximately Rs 3,502.31 crore.

The price reductions are substantial, with 679 brands recording cuts exceeding 50% and the steepest decline reaching 96.45%. Notable examples include Zydus Lifesciences' Bryxta injection dropping from Rs 25,995 to Rs 3,318, and RPG Life Sciences' Palbopro capsule falling from Rs 40,421 to Rs 2,720. The directive applies to both currently available medicines and 10-15 products awaiting domestic launch, ensuring immediate margin control upon market entry under notification SO 5690 (E). While the financial relief is significant, implementation challenges persist. Experts note that the cap regulates distributor and retailer margins rather than manufacturer base prices, meaning expensive patented therapies may see limited reduction.